MedTrace Logo

CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma

NCT05613348 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2024-03-18

No results posted yet for this study

Summary

This study aims to evaluate the safety and efficacy of humanized Anti-CD19 Chimeric Antigen Receptor-T cell (CAR19T2 T cell) in children with refractory/relapsed B-cell acute lymphoblastic leukemia/lymphoma.

Conditions

Interventions

BIOLOGICAL

CD19 CAR T-Cell(CAT19T2)

Drug: Fludarabine， Administered intravenously Drug: Cyclophosphamide， Administered intravenously

Sponsors & Collaborators

  • Guangdong Zhaotai Cell Bio-tech Co., LTD

    collaborator UNKNOWN

  • Zhujiang Hospital

    lead OTHER

Principal Investigators

  • Lihua Yang · Zhujiang Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2025-12-01
Completion
2028-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05613348 on ClinicalTrials.gov